CAR-T Cell Products Market
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary
2.Global CAR-T Cell Products Market Introduction
2.1.Global CAR-T Cell Products Market - Txonomy
2.2.Global CAR-T Cell Products Market - Definitions
2.2.1.By Indication
2.2.2.By Drug Type
2.2.3.By End-user
2.2.4.By Region
3.Global CAR-T Cell Products Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global CAR-T Cell Products Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global CAR-T Cell Products Market By Indication, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Leukemia
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Lymphoma
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Multiple Myeloma
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Autoimmune Disorders
5.4.1.Autoimmune Disorders Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6.Global CAR-T Cell Products Market By Drug Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Abecma
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breyanzi
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Carvyakti
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Kymriah
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Tecartus
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Yescarta
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7.Global CAR-T Cell Products Market By End-user, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Treatment Centers
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global CAR-T Cell Products Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America CAR-T Cell Products Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Leukemia
9.1.2.Lymphoma
9.1.3.Multiple Myeloma
9.1.4.Autoimmune Disorders
9.1.5.Others
9.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Abecma
9.2.2.Breyanzi
9.2.3.Carvyakti
9.2.4.Kymriah
9.2.5.Tecartus
9.2.6.Yescarta
9.2.7.Others
9.3. End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Hospitals
9.3.2.Cancer Treatment Centers
9.3.3.Others
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe CAR-T Cell Products Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Leukemia
10.1.2.Lymphoma
10.1.3.Multiple Myeloma
10.1.4.Autoimmune Disorders
10.1.5.Others
10.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Abecma
10.2.2.Breyanzi
10.2.3.Carvyakti
10.2.4.Kymriah
10.2.5.Tecartus
10.2.6.Yescarta
10.2.7.Others
9.3. End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Hospitals
10.3.2.Cancer Treatment Centers
10.3.3.Others
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) CAR-T Cell Products Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Leukemia
11.1.2.Lymphoma
11.1.3.Multiple Myeloma
11.1.4.Autoimmune Disorders
11.1.5.Others
11.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Abecma
11.2.2.Breyanzi
11.2.3.Carvyakti
11.2.4.Kymriah
11.2.5.Tecartus
11.2.6.Yescarta
11.2.7.Others
10.3. End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Hospitals
11.3.2.Cancer Treatment Centers
11.3.3.Others
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America CAR-T Cell Products Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Leukemia
12.1.2.Lymphoma
12.1.3.Multiple Myeloma
12.1.4.Autoimmune Disorders
12.1.5.Others
12.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Abecma
12.2.2.Breyanzi
12.2.3.Carvyakti
12.2.4.Kymriah
12.2.5.Tecartus
12.2.6.Yescarta
12.2.7.Others
11.3. End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Hospitals
12.3.2.Cancer Treatment Centers
12.3.3.Others
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Meair pollution control systemsico
12.4.3.Rest of LA
13.Middle East and Africa CAR-T Cell Products Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Leukemia
13.1.2.Lymphoma
13.1.3.Multiple Myeloma
13.1.4.Autoimmune Disorders
13.1.5.Others
13.2. Drug Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Abecma
13.2.2.Breyanzi
13.2.3.Carvyakti
13.2.4.Kymriah
13.2.5.Tecartus
13.2.6.Yescarta
13.2.7.Others
12.3. End-user Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Hospitals
13.3.2.Cancer Treatment Centers
13.3.3.Others
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.Novartis AG
14.2.2.Bristol-Myers Squibb Company
14.2.3.Gilead Sciences, Inc. (Kite Pharma)
14.2.4.Johnson & Johnson
14.2.5.Eli Lilly and Company
14.2.6.Sorrento Therapeutics, Inc.
14.2.7.ACROBiosystems
14.2.8.Celyad Oncology
14.2.9.Sangamo Therapeutics, Inc.
14.2.10.Servier Laboratories
14.2.11.Noile-Immune Biotech, Inc.
14.2.12.Miltenyi Biotec
15. Research Methodology
16. Appendiair pollution control systems and Abbreviations
Novartis AG
Bristol-Myers Squibb Company
Gilead Sciences, Inc. (Kite Pharma)
Johnson & Johnson
Eli Lilly and Company
Sorrento Therapeutics, Inc.
ACROBiosystems
Celyad Oncology
Sangamo Therapeutics, Inc.
Servier Laboratories
Noile-Immune Biotech, Inc.
Miltenyi Biotec